Autometallographically enhanced Nanogold probes have proved highly sensitive both for direct detection of in situ hybridization probes, and when used in conjunction with Catalyzed Reporter Deposition (CARD, also known as Tyramide Signal Amplification or TSA). This method was used to detect Human Papilloma virus type 16 in SiHa cells known to contain only 1-2 copies of the viral genome more reliably than enzymatic detection. We propose a Nanogold chromogenic in situ assay for the detection of amplification of the proto-oncogene Her-2/neu in breast carcinoma specimens. This is the most widely accepted indicator of aggressive malignant behavior; the proposed assay will be used for early detection of potential malignancy and indication for monoclonal antibody or Herceptin therapy. Unlike fluorescent in situ hybridization (FISH) which requires fluorescent optics not routinely available in many pathology laboratories, Nanogold detection produces a dense black signal that is readily visualized by conventional optical microscopy. The new reagents and procedures will combine the high sensitivities of amplification with the ability of Nanogold to access restricted antigens, and the macromolecular spatial resolution which is only available with gold probes: the same sample may be processed for localization of the target sequence at the macromolecular level if desired.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41CA083618-01
Application #
6021551
Study Section
Special Emphasis Panel (ZRG1-ONC (01))
Program Officer
Couch, Jennifer A
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
1
Fiscal Year
2000
Total Cost
$128,363
Indirect Cost
Name
Nanoprobes, Inc.
Department
Type
DUNS #
784163446
City
Yaphank
State
NY
Country
United States
Zip Code
11980